Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2068-2073

  Lorenzen, S ^a   Thuss Patience, P ^b   Al Batran, S E ^c   Lordick, F ^d   Haller, B ^e   Schuster, T ^e   Pauligk, C ^c   Luley, K ^f   Bichev, D ^b   Schumacher, G ^g   Homann, N ^h  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c KRANKENHAUS NORDWEST   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g KLINIKUM BRAUNSCHWEIG   (Germany)

^h Klinikum Wolfsburg   (Germany)

Author keywords

Docetaxel; Esophagogastric adenocarcinoma; Pathologic complete response; Preoperative

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS FISTULA; PATHOLOGIC COMPLETE RESPONSE; PNEUMONIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; SURGICAL INFECTION; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR LOCALIZATION;

DOCETAXEL; ESOPHAGOGASTRIC ADENOCARCINOMA; PATHOLOGIC COMPLETE RESPONSE; PREOPERATIVE;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL; SURVIVAL RATE; TAXOIDS; VITAMIN B COMPLEX;

EID: 84881254895     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt141     Document Type: Article

References (23)

1. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
2. Ychou M, Boige V, Pignon JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-linetherapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
4. Lorenzen S, Hentrich M, Haberl C et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 2007; 18: 1673-1679.
5. Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
6. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; 3: CD004064.
7. Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2010; 362: 858-859.
8. Homann N, Pauligk C, Luley K et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer 2012; 130: 1706-1713.
9. Thuss-Patience PC, Hofheinz RD, Arnold D et al. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2012; 23: 2827-2834.
10. Lordick F, Stein HJ, Peschel C et al. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004; 91: 540-551.
11. Becker K, Langer R, Reim D et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011; 253: 934-939.
12. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
13. Fields RC, Strong VE, Gonen M et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer 2011; 104: 1840-1847.
14. Schuhmacher C, Gretschel S, Lordick F et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218.
15. Burzykowski T, Bang Y, on behalf of the GASTRIC project. Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol 2009; 27: 15s. (suppl; abstr 4517).
16. Sobin LH, Wittekind Ch (eds). TNM Classification of Malignant Tumors, 6th edition. Hoboken, NJ: John Wiley & Sons 2002.
17. Reim D, Gertler R, Novotny A et al. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012; 19: 2108-2118.
18. Becker K, Mueller JD, Schulmacher C et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530.
19. Kattan MW, Karpeh MS, Mazumdar M et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21: 3647-3650.
20. Kelsen DP, Winter KA, Gunderson LL et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719-3725.
21. Mansour JC, Tang L, Shah M et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 2007; 14: 3412-3418.
22. Brucher BL, Becker K, Lordick F et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106: 2119-2127.
23. Al-Batran SE, Hofheinz R, Homann N et al. A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3. J Clin Oncol 2012; 30. (suppl; abstr 4090).